Health Care & Life Sciences » Biotechnology | Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
31,146.00
24,189.00
20,440.00
16,520.00
23,910.00
17,504
Total Accounts Receivable
2,310.00
3,460.00
3,026.00
2,057.00
1,488.00
1,504
Other Current Assets
1,717.00
1,351.00
1,100.00
1,040.00
576.00
779
Total Current Assets
35,173.00
29,000.00
24,566.00
19,617.00
25,974.00
19,787
Net Property, Plant & Equipment
275.00
387.00
198.00
45.00
29.00
36
Other Assets
72.00
-
-
-
-
-
Total Assets
35,520.00
29,387.00
24,764.00
19,662.00
26,003.00
19,823
Accounts Payable
2,545.00
2,792.00
1,940.00
2,497.00
1,558.00
Other Current Liabilities
4,952.00
4,701.00
3,813.00
2,762.00
2,555.00
Total Current Liabilities
7,497.00
7,493.00
5,753.00
5,259.00
4,113.00
Other Liabilities
-
206.00
176.00
130.00
124.00
Total Liabilities
7,497.00
7,699.00
5,929.00
5,389.00
4,237.00
Common Equity (Total)
28,023.00
21,688.00
18,835.00
14,273.00
21,766.00
Total Shareholders' Equity
28,023.00
21,688.00
18,835.00
14,273.00
21,766.00
Total Equity
28,023.00
21,688.00
18,835.00
14,273.00
21,766.00
Liabilities & Shareholders' Equity
35,520.00
29,387.00
24,764.00
19,662.00
26,003.00

About Cyclacel Pharmaceuticals

View Profile
Address
200 Connell Drive
Berkeley Heights New Jersey 07922
United States
Employees -
Website http://www.cyclacel.com
Updated 07/08/2019
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.